Shield Therapeutics (LSE:STX) has applied to the London Stock Exchange for a block listing covering 15,000,000 ordinary shares, which are intended for use under the company’s Retention and Performance Share Plan. The shares are expected to be admitted to trading on 23 December 2025.
The move is designed to support the company’s incentive framework as it continues to commercialise its iron deficiency treatment ACCRUFeR®. Management said the block listing will provide additional flexibility in rewarding and retaining key personnel as the business seeks to build on its position within the global iron deficiency market, estimated to be worth around $2.3 billion.
From a market standpoint, Shield Therapeutics is benefiting from supportive technical momentum and recent corporate developments. However, these positives are tempered by ongoing financial pressures and valuation concerns, with funding stability remaining a key consideration for investors.
More about Shield Therapeutics
Shield Therapeutics plc is a commercial-stage pharmaceutical company focused on the development and global commercialisation of ACCRUFeR®/FeRACCRU® (ferric maltol), an oral treatment for iron deficiency with or without anaemia. The company operates through partnerships and licensing arrangements, with products marketed across the US, UK, Europe, Canada, China, South Korea, Japan, and other international markets.
Leave a Reply